Speaker(s): 

Bianca Harper-Rodriguez, PharmD, PGY1 Pharmacy resident, Geisinger - has nothing to disclose.

Moderator(s): 

Christopher DeFrancesco, PharmD, Clinical Pharmacist / Asst Pharmacy Residency Program Director Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Define drug-induced lupus(DIL) and how it differs from systemic lupus erythematosus (SLE)

2. Explore the possible physiological mechanisms leading to DIL​

3. Identify high‑risk, commonly implicated medications​ that are associated with DIL

4. Recognize clinical and laboratory features of DIL that are either shared or different from other lupus types​

5. Review strategies for management of DIL 

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Christopher DeFrancesco PharmD, RPH; Anil Singh MD; Roop Parlapalli, MD, FHM, FACP; Carolyn Chilewshi, PA-C; Emilie Detweiler, PharmD, RPh; Alexa Kerecman, CRNP; John Sacino, CPhT, and Miranda Steigler, PharmD, RPh have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.